CoChat

Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis

Open access
Fu, Rong, Zu, Shi-Jia, Liu, Yan-Jun, Li, Jia-Cheng, Dang, Wen-Zhen, Liao, Li-Ping, Liu, Li-Ping, Chen, Pan-Yu, Huang, He-Ming, Wu, Kang-Hui, Zhou, Bing, Pan, Qin, Luo, Cheng, Zhang, Yuan-Yuan, Li, Guang-Ming · 2022 · Bioengineered

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Liver fibrosis occurs following inflammation triggered by the integrated actions of activated liver-resident macrophages (Kupffer cells) and hepatic stellate cells (HSCs), and the multiplicity of these mechanisms complicates drug therapy. Here, we demonstrate that the selective bromodomain and extra-terminal (BET) bromodomain inhibitor compound38 can block both the Janus kinase-signal transducer and activator of transcription and mitogen-activated protein kinase signaling pathways in macrophages, which decreased their secretion of proinflammatory cytokines in a dose-dependent manner. The inactivation of macrophages attenuated lipopolysaccharide-induced injurious inflammation concurrent with a reduction in F4/80+ cells, proinflammatory cytokine levels, and neutrophil infiltration. Moreover, compound 38 inhibited the Wnt/β-catenin and transforming growth factor-beta/SMAD signaling pathways to abolish the activation of HSCs. In vivo, compound 38 significantly decreased the collagen deposition and fibrotic area of a CCl4-induced liver fibrosis model, and restored the deficiency of activated HSCs and the upregulation of liver inflammation. These results highlight the potential role of compound 38 in treating liver fibrosis considering its simultaneous inhibitory effects on liver inflammation and related fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21655979.2022.2066756

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
Figure 1. The selective BET inhibitor compound 38 inhibits the LPS-induced inflammatory response.
Figure 1. The selective BET inhibitor compound 38 inhibits the LPS-induced inflammatory response.CC BY · PubMed Central
Figure 2. Compound 38 treatment attenuates inflammatory responses in the LPS/ GalN-induced acute liver injury (ALI) mouse model in vivo.
Figure 2. Compound 38 treatment attenuates inflammatory responses in the LPS/ GalN-induced acute liver injury (ALI) mouse model in vivo.CC BY · PubMed Central
Figure 3. Compound38 inhibits pro-inflammatory gene expression and blocks the inflammatory pathway.
Figure 3. Compound38 inhibits pro-inflammatory gene expression and blocks the inflammatory pathway.CC BY · PubMed Central
Figure 4. Compound 38 treatment inhibited hepatic stellate cell (HSC) activation.
Figure 4. Compound 38 treatment inhibited hepatic stellate cell (HSC) activation.CC BY · PubMed Central
Figure 5. Compound 38 treatment reduces liver inflammation and fibrosis.
Figure 5. Compound 38 treatment reduces liver inflammation and fibrosis.CC BY · PubMed Central
Figure 6. Compound 38 blocks fibrosis-related pathway activation in LX2 cells.
Figure 6. Compound 38 blocks fibrosis-related pathway activation in LX2 cells.CC BY · PubMed Central
Figure 7. (a) The viability of four kinds of cells was assessed using the Cell Titer-Glo assay after 24-h administration by compound 38. (b) Four-hour administration with the selective BET inhibitor compound 38 downregulated the mRNA levels of Il-1β, Il-6, and Tnf-α in mouse Kupffer cells.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to the TGF-β-induced group. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 compared to the control group.
Figure 7. (a) The viability of four kinds of cells was assessed using the Cell Titer-Glo assay after 24-h administration by compound 38. (b) Four-hour administration with the selective BET inhibitor compound 38 downregulated the mRNA levels of Il-1β, Il-6, and Tnf-α in mouse Kupffer cells.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to the TGF-β-induced group. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 compared to the control group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 12

Metadata

Authors
Fu, R., Zu, S.-J., Liu, Y.-J., Li, J.-C., Dang, W.-Z., Liao, L.-P., Liu, L.-P., Chen, P.-Y., Huang, H.-M., Wu, K.-H., Zhou, B., Pan, Q., Luo, C., Zhang, Y.-Y., & Li, G.-M.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, Zuchongzhi District, Shanghai, China
  • Chinese Academy of Sciences (CN)
  • Department of Gastroenterology, Xinhua Hospital, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Yangpu District, China
Venue
Bioengineered
Published
2022-04-01
Volume
13
Issue
4
Pages
10914-10930
ISSN
  • 2165-5979 (ISSN-L)
  • 2165-5987
OpenAlex
W4225274129
Cited by
12
References
68
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • Bioengineered (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82170617)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
liver fibrosis, liver inflammation, Kupffer cells, hepatic stellate cells, BET bromodomain, JAK/STAT signaling, MAPK signaling, Wnt/β-catenin signaling, TGF-β/Smad signaling, inflammatory cytokines, neutrophil infiltration, collagen deposition, CCl4-induced fibrosis
MeSH terms
Humans, Inflammation, Liver Cirrhosis, Macrophages, Cytokines, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis. https://app.cochat.ai/papers/10.1080/21655979.2022.2066756
The paper
Fu, R., Zu, S.-J., Liu, Y.-J., Li, J.-C., Dang, W.-Z., Liao, L.-P., Liu, L.-P., Chen, P.-Y., Huang, H.-M., Wu, K.-H., Zhou, B., Pan, Q., Luo, C., Zhang, Y.-Y., & Li, G.-M. (2022). Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis. Bioengineered. https://doi.org/10.1080/21655979.2022.2066756

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.